Self- vs balloon-expandable TAVR in patients with small aortic annuli: SMART trial primary outcomes

A. Sticchi interviews H. C. Herrmann about the primary outcomes from the randomized Smart Trial which he presented at the #ACC24
Patients with severe aortic stenosis and small aortic annuli, typically female and often underrepresented in clinical trials, are at risk for impaired valvular hemodynamics and associated adverse cardiovascular outcomes following TAVR. The primary outcomes of the SMART trial revealed superior valve performance with the self-expanding Evolut valve, although clinical outcomes were similar at one year. Future research will explore long-term implications and patient subgroup variations in valve durability and outcomes.
More news about the ACC.24 on PCRonline: www.pcronline....